Story perspectives

Pelacarsen Fails Phase 3, Novartis Misses Cardiovascular Endpoint

9/10/2026

Summary

Story summary

Novartis announced its cholesterol drug pelacarsen failed to reduce cardiovascular events in a Phase 3 trial.
The Lp(a)HORIZON Phase 3 trial enrolled more than 8,300 patients with cardiovascular disease.
Pelacarsen lowered lipoprotein(a) levels by up to 80% but missed the primary endpoint.
Novartis shares fell about 3% in extended trading; Ionis dropped 10% and Amgen about 5%.
Novartis CMO Shreeram Aradhye said full data will be presented at a future medical congress.

1 of 1

Story summary

Novartis announced its cholesterol drug pelacarsen failed to reduce cardiovascular events in a Phase 3 trial.
The Lp(a)HORIZON Phase 3 trial enrolled more than 8,300 patients with cardiovascular disease.
Pelacarsen lowered lipoprotein(a) levels by up to 80% but missed the primary endpoint.
Novartis shares fell about 3% in extended trading; Ionis dropped 10% and Amgen about 5%.
Novartis CMO Shreeram Aradhye said full data will be presented at a future medical congress.